# China NMPA Drug Inspection - Hubei Qingda Traditional Chinese Medicine Pieces Co., Ltd. - Madder root (processed)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-qingda-traditional-chinese-medicine-pieces-co-ltd/9e2c218e-5320-407d-ba7c-35ab5743409d/
Source feed: China

> China NMPA drug inspection for Hubei Qingda Traditional Chinese Medicine Pieces Co., Ltd. published January 18, 2019. Drug: Madder root (processed). On January 16, 2019, the Heilongjiang Provincial Drug Administration announced findings regarding nine batches of substa

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Heilongjiang Provincial Drug Administration Regarding 9 Batches of Substandard Drugs (Traditional Chinese Medicine Decoction Pieces) (Issue 1, 2019)
- Company Name: Hubei Qingda Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2019-01-18
- Drug Name: Madder root (processed)
- Inspection Finding: Substandard medicine
- Action Taken: Substandard drugs were seized and confiscated, and their sale and use were ordered to cease; cases of illegal activity were investigated and dealt with according to law, and the results were made public.
- Summary: On January 16, 2019, the Heilongjiang Provincial Drug Administration announced findings regarding nine batches of substandard drug products, primarily traditional Chinese medicine decoction pieces, discovered through market surveillance. The identified manufacturers include Shanghai Huangxiang Tieli Lantian Pharmaceutical Co., Ltd., Hunan Wuzhoutong Pharmaceutical Co., Ltd., Bozhou Yonggang Decoction Pieces Factory Co., Ltd., Bozhou Zhang Zhongjing Traditional Chinese Medicine Decoction Pieces Co., Ltd., Anhui People's Traditional Chinese Medicine Pieces Co., Ltd., Anhui Hejitang Traditional Chinese Medicine Pieces Co., Ltd., Anhui Guanghe Traditional Chinese Medicine Co., Ltd., and Harbin Qigongtang Traditional Chinese Medicine Pieces Co., Ltd. The main issue was the production and distribution of drugs failing to meet quality standards, encompassing products like Troxerutin Tablets, Asarum for Injection, Polygala tenuifolia, vinegar and myrrh, papaya, radish seed, jujube seed (roasted), oyster shell, and madder root. In response, local drug regulatory authorities promptly implemented control measures, including sealing and seizing the affected batches and directing units to cease sales and usage. The regulatory framework for these actions is based on Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. Required actions include thorough investigation and prosecution of all illegal activities related to the production, sale, and use of these substandard drugs. Furthermore, responsible departments must publicly announce the handling results for the involved enterprises or units within three months and report the outcomes to the Provincial Drug Administration.

Company: https://www.globalkeysolutions.net/companies/hubei-qingda-traditional-chinese-medicine-pieces-co-ltd/dfdea9b6-3c7b-4587-b754-eb9cd4469c47/